Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
暂无分享,去创建一个
Y. Miyagi | Y. Kameda | Y. Sakuma | K. Noda | M. Yoshihara | S. Matsukuma | E. Tsuchiya | Yoshiyasu Nakamura | H. Nakayama
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] Y. Bang,et al. Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation , 2006, Clinical Cancer Research.
[3] A. Gazdar,et al. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.
[4] Y. Ishikawa,et al. High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs , 2005, Journal of Cancer Research and Clinical Oncology.
[5] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[6] M. Kris,et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Marchetti,et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[9] M. Beasley,et al. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. , 2009, Archives of pathology & laboratory medicine.
[10] S. Toyooka,et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W. Park,et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas , 2005, Virchows Archiv.
[13] Y. Shimosato,et al. Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.
[14] M. Sonobe,et al. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma , 2005, British Journal of Cancer.
[15] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[16] S. Toyooka,et al. PD-160 The relationship between epidermal growth factor receptor (EGFR) mutations and clinicopathologic features in non-small cell lung cancers , 2005 .
[17] H. Sasaki,et al. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. , 2006, Lung cancer.
[18] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[19] M. Spitz,et al. Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Y. Yatabe,et al. EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.
[21] Hai-sheng Zhou,et al. Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[22] K. Sugimachi,et al. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] A. Marchetti,et al. BRONCHIOLOALVEOLAR LUNG CARCINOMAS: K‐ras MUTATIONS ARE CONSTANT EVENTS IN THE MUCINOUS SUBTYPE , 1996, The Journal of pathology.
[24] J. Minna,et al. Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.
[25] Y. Miyagi,et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. , 2006, The Journal of molecular diagnostics : JMD.
[26] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[27] S. Barsky,et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features , 1994, Cancer.
[28] T. Oda,et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. , 2001, Cancer research.
[29] Setsuo Hirohashi,et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995 .
[30] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] P. Jänne,et al. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Huqun,et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.
[33] T. Chou,et al. Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.